mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?

Bibliographic Details
Main Authors:	David J. Kwiatkowski, Nikhil Wagle, MD
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396414000632

Similar Items

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Overview of Research into mTOR Inhibitors
by: Beibei Mao, et al.
Published: (2022-08-01)

Targeting ganglioneuromas with mTOR inhibitors
by: Ting Tao, et al.
Published: (2021-01-01)

Cancer and mTOR inhibitors in kidney transplantation recipients
by: Chih-Chin Kao, et al.
Published: (2018-11-01)

Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
by: Jingwen Cao, et al.
Published: (2016-01-01)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
by: Victor H. Villar, et al.
Published: (2017-05-01)

mTOR inhibitors in a patient with lupus nephritis; why not?
by: Raquel Berzal, et al.
Published: (2023-12-01)

mTOR inhibitors in a patient with lupus nephritis; why not?
by: Raquel Berzal, et al.
Published: (2023-12-01)

Recent advances and limitations of mTOR inhibitors in the treatment of cancer
by: Eunus S. Ali, et al.
Published: (2022-09-01)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
by: Lampidis Theodore, et al.
Published: (2005-07-01)

mTOR, autophagy and reprogramming
by: Bor Luen eTang
Published: (2014-01-01)

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
by: Liu, Qingsong, et al.
Published: (2015)

Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
by: Molly C. McNamara, et al.
Published: (2022-11-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
by: Pezzicoli G, et al.
Published: (2021-10-01)

Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia
by: Hadley, G, et al.
Published: (2019)

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
by: Alexandre el Hage, et al.
Published: (2021-03-01)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
by: Letizia Todeschini, et al.
Published: (2023-06-01)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
by: Mathis Wehming, et al.
Published: (2023-02-01)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
by: Wei Zhao, et al.
Published: (2023-06-01)

Effects of mTOR Inhibitors on Components of the Salvador-Warts-Hippo Pathway
by: Julian A. Martinez-Agosto, et al.
Published: (2012-10-01)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
by: Kay Andrea, et al.
Published: (2009-10-01)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
by: Reece Jefferies, et al.
Published: (2022-02-01)

Management of mTOR inhibitors oral mucositis: current state of knowledge
by: Calvo Anne Sophie, et al.
Published: (2019-01-01)

Perivascular Epithelioid Cell Tumors (PEComas) Refractory to mTOR Inhibitors
by: San-Chi Chen, et al.
Published: (2014-09-01)

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
by: Yimei Feng, et al.
Published: (2021-01-01)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
by: George K. E. Umanah, et al.
Published: (2022-08-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab.
by: Patel, N, et al.
Published: (2017)

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
by: Lei Cheng, et al.
Published: (2022-05-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
by: Neel Patel, et al.
Published: (2017-05-01)

mTOR Signalling, Nutrients and Disease
by: Goberdhan, D, et al.
Published: (2008)

mTOR Signaling: Recent Progress
by: Antonios N. Gargalionis, et al.
Published: (2024-02-01)

The mTOR pathway in the antiphospholipid syndrome
by: Ji Lanlan, et al.
Published: (2023-12-01)

mTOR Signaling in Metabolism and Cancer
by: Shile Huang
Published: (2020-10-01)

The Translational Regulation in mTOR Pathway
by: Miaomiao Yang, et al.
Published: (2022-06-01)

mTOR Pathways in Cancer and Autophagy
by: Mathieu Paquette, et al.
Published: (2018-01-01)

Targeting mTOR for cancer therapy
by: Hui Hua, et al.
Published: (2019-07-01)

Biodegradable Stent with mTOR Inhibitor-Eluting Reduces Progression of Ureteral Stricture
by: Dong-Ru Ho, et al.
Published: (2021-05-01)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
by: Micol Silic-Benussi, et al.
Published: (2023-03-01)